07:38 AM EDT, 06/30/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that results from a phase 3 study demonstrated the "superior relative vaccine efficacy" of its mRNA-1010 seasonal influenza vaccine candidate compared with a licensed standard-dose seasonal influenza vaccine in adults aged at least 50 years old.

The company said mRNA-1010 had a relative vaccine efficacy of 26.6% in the study's overall population and demonstrated strong relative vaccine efficacy for each influenza strain contained in the vaccine. The product candidate's safety and tolerability were also consistent with results from a previous phase 3 study, said Moderna ( MRNA ).

Moderna ( MRNA ) said it is set to present the study's data at an upcoming medical meeting and will discuss mRNA-1010's filing submissions with relevant regulators.